4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000899243-16-028295
CIK 0001369786operating
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 6:11 PM ET
Size
13.0 KB
Accession
0000899243-16-028295
Insider Transaction Report
Form 4
Greve Jeffrey W.
Vice President, Controller
Transactions
- Disposition to Issuer
Stock Option to Buy
2016-08-29$1.59/sh−8,865$14,095→ 0 totalExercise: $20.16Exp: 2024-02-18→ Common Stock (8,865 underlying) - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−4,962$107,924→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$5.30/sh−8,604$45,601→ 0 totalExercise: $16.45Exp: 2023-02-21→ Common Stock (8,604 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−10,507$75,020→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (10,507 underlying)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these restricted shares were canceled and converted into the right to receive $21.75 per share, without interest, less any applicable withholding taxes (the "Merger Consideration").
- [F2]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
- [F3]Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
- [F4]Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Aug 30, 8:00 PM ET
- Accepted
- Aug 31, 6:11 PM ET
- Size
- 13.0 KB